Real-world Daptomycin Use in Chinese ICUs

Sichuan University

Status: Completed

Conditions: Daptomycin; Intensive Care Unit; Real-world Study

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT03588637

HX 00147

Details and patient eligibility

About

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.

Enrollment: 200 patients

Sex: All

Ages: 1 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient who received at least one dose of daptomycin

Exclusion criteria

• No

Trial design

200 participants in 1 patient group

Study population

Description:

Patient who receive at least one dose of daptomycin

Treatment:

Other: No intervention